Literature DB >> 785429

Assessment of vaccine efficacy by challenge studies in man.

D A Tyrrell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 785429      PMCID： PMC2496319          DOI： 10.1136/pgmj.52.608.379

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  4 in total

1.  A comparison of live and killed influenza-virus vaccines. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines.

Authors:  A S Beare; D Hobson; S E Reed; D A Tyrrell
Journal:  Lancet       Date:  1968-08-24       Impact factor: 79.321

2.  Potentiation of the antibody response to inactivated A2-Hong Kong vaccines by previous heterotypic influenza virus infection.

Authors:  C W Potter; R Jennings; W M Marine; C McLaren
Journal:  Microbios       Date:  1973 Sep-Oct

3.  Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2 ) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines.

Authors:  D S Freestone; S Hamilton-Smith; G C Schild; R Buckland; S Chinn; D A Tyrrell
Journal:  J Hyg (Lond)       Date:  1972-09

4.  Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine.

Authors:  C W Potter; R Jennings; C McLaren; A Clarke
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574
  4 in total
  2 in total

1.  The response to inactivated influenza A (H3N2) vaccines: the development and effect of antibodies to the surface antigens.

Authors:  A F Smith; J R Davies
Journal:  J Hyg (Lond)       Date:  1977-06

Review 2.  Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planning.

Authors:  J McVernon; C T McCaw; J D Mathews
Journal:  Influenza Other Respir Viruses       Date:  2007-03       Impact factor: 4.380
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.